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Abstract
Introduction: Choriocarcinoma is a highly malignant tumor of trophoblastic origin. Most cases present within one
year of the antecedent pregnancy (molar or non-molar). However, very rarely, choriocarcinoma can develop from
germ cells or from dedifferentiation of endometrial carcinoma into choriocarcinoma. This article concerns a case of
choriocarcinoma developing 38 years after the patient’s last pregnancy and 23 years after menopause.
Case presentation: A 73-year-old African-American woman presented with a three-week history of vaginal
bleeding. A vaginal mass was seen on pelvic examination. Ultrasonography showed a thickened complex
endometrial echo. Her b-human chorionic gonadotrophin level was found to be elevated (2,704,040 mIU/mL).
Vaginal and uterine biopsies were suggestive of choriocarcinoma. Immunohistochemistry tests were positive for b-
human chorionic gonadotrophin as well as cytokeratin and negative for octamer binding transcription factor 3/4
and a-fetoprotein, supporting the diagnosis of choriocarcinoma. A combination of etoposide, methotrexate, and
dactinomycin, followed by cyclophosphamide and vincristine (the so-called EMA/CO regimen) was initiated. After
seven cycles of chemotherapy, her b-human chorionic gonadotrophin level dropped below 5 mIU/mL. Our patient
is being followed up at our oncology institute.
Conclusions: We report an extremely rare case of choriocarcinoma arising 23 years after menopause. A
postmenopausal woman presenting with vaginal bleed from a mass and b-human chorionic gonadotrophin
elevation should be evaluated by immunohistochemical analysis to rule out the possibilities of a germ cell origin of
the tumor or dedifferentiation of an epithelial tumor. Absence of octamer binding transcription factor 3/4, a-
fetoprotein and CD-30 staining helps in exclusion of most germ cell tumors. DNA polymorphism studies can be
used to differentiate between gestational and non-gestational tumor origin. These require fresh tissue samples and
are time consuming. Finally, the effective first-line therapy for b-human chorionic gonadotrophin-producing high-
risk gestational as well as non-gestational trophoblastic tumors is combination chemotherapy (the EMA/CO
regimen). Therefore, treatment should be commenced when a potential diagnosis of metastatic trophoblastic
tumor is being considered.
Introduction
Choriocarcinoma is a highly malignant trophoblastic
tumor composed of two types of cells, syncytiotropho-
blasts and cytotrophoblasts. The syncytiotrophoblast is
the differentiated hormone secreting component [1,2].
Most cases of choriocarcinoma are intra-uterine and of
gestational origin. Extrauterine gestational choriocarcino-
mas may also arise at a site of ectopic pregnancy. The
non-gestational choriocarcinomas are believed to develop
from pluripotent germ cells, most commonly arising in
the gonads. Finally, various poorly differentiated carcino-
mas may show focal area of choriocarcinomatous differ-
entiation [1,3]. Gestational choriocarcinoma is a rare
complication of pregnancy (incidence of one in 20,000 to
o n ei n2 5 , 0 0 0i nw e s t e r nc o u n t r i e s )a n du s u a l l ya r i s e s
from a prior molar pregnancy or rarely a non-molar
gestation, within one year of the antecedent pregnancy
[4]. Choriocarcinoma in postmenopausal woman is very
rare, however a few cases of choriocarcinoma developing
after a long latent period from last pregnancy have been
reported [4-7]. Here, we describe a case of choriocarci-
noma in a 73-year-old woman developing 38 years after
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any medium, provided the original work is properly cited.her last pregnancy and 23 years after her last menstrual
period.
Case presentation
A 73-year-old African-American woman, gravida 4 para
4, presented with a three-week history of postmenopau-
sal vaginal bleeding, with associated suprapubic pain
and urinary retention for the past two days. A pelvic
exam revealed a 5 cm fungating left vaginal wall mass
extending to the bladder trigone, and a closed cervix.
There was no cervical motion tenderness and no palp-
able adnexal mass. Our patient had suprapubic tender-
ness with no palpable mass in her abdomen. All other
examinations were unremarkable. Pelvic and transvagi-
nal sonograms showed a thickened complex endometrial
echo (2.4 cm) and her uterus measured 9.7×6.2×5.4 cm.
Her ovaries were normal in size (2.5×1.8×1.5 cm). Com-
puted tomography (CT) scans of the chest, abdomen
and pelvis showed a heterogeneous vagina and two
hepatic masses measuring 7.7 cm and 3.4 cm, respec-
tively. A CT scan of her brain with contrast and a bone
scan did not show any evidence of metastasis. Two
biopsies were taken from the endometrial and vaginal
wall masses. Grossly, the endometrial biopsy consisted
of multiple fragments of blood clots and grayish tissue,
3.9 cm in aggregate. The vaginal wall biopsy consisted
of multiple fragments of brown-red, soft and firm tissue,
measuring 3.3 cm in aggregate. Histological examination
was suggestive of choriocarcinoma. The non-lesional
endometrium showed decidualization (Figures 1 and 2).
On immunohistochemistry tumor cells appeared positive
for b-human chorionic gonadotrophin (b-hCG) (Figure 3)
and cytokeratins (AE-1, AE-2) and negative for octamer
binding transcription factor (OCT)-3/4, a-fetoprotein
(AFP) and CD-30. There was no histological evidence of
any other type of malignancy (no germ cell component,
no endometrial carcinoma). Percutaneous CT-directed
core needle biopsy of the larger liver lesion demonstrated
extensive necrosis with atypical cells suggestive of
malignancy.
Our patient’s b-hCG level was 2,704,040 mIU/mL.
Cancer antigen 125 (CA-125) and AFP levels were nor-
mal. Chemotherapy with etoposide, methotrexate and
dactinomycin, followed by cyclophosphamide and vin-
cristine (the so-called EMA/CO regimen) was initiated.
Her b-hCG level at follow-up (after the first cycle of
chemotherapy) was 646 mIU/mL. Her vaginal bleeding
and urinary symptoms resolved after the first cycle of
chemotherapy. After seven cycles of EMA/CO che-
motherapy her b-hCG level dropped below 5 mIU/mL.
A repeat CT scan (after four months) showed a normal-
appearing uterus and a decrease in size of the metastatic
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Figure 1 Endometrial biopsy showing choriocarcinoma with
decidual reaction.
Vaginal biopsy: Chorio carcinoma
Figure 2 Vaginal biopsy showing choriocarcinoma.
Endometrial biopsy: Beta HCG staining
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Figure 3 Immunohistochemistry analysis of endometrial biopsy
specimen. Cytotrophoblasts and syncytiotrophoblasts were stained
with b-human chorionic gonadotrophin (b-hCG) antibody.
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clinically asymptomatic and is on regular follow-up at
o u rc a n c e rc e n t e r .H e rb-hCG level stayed below 5
mIU/mL at one year of follow-up.
Our patient’s obstetric history was significant for four
normal vaginal deliveries (the last at 35 years of age)
and menopause at 50 years of age. She denied any
episode of postmenopausal bleeding before this
presentation.
Discussion
Choriocarcinomas can be divided into two types: gesta-
tional and non-gestational. Gestational choriocarcinomas
mostly occur in woman of reproductive age, usually
within one year following a molar or non-molar preg-
nancy. Non-gestational choriocarcinomas can arise from
germ cell or trophoblastic differentiation within endo-
metrial carcinomas. Extraovarian germ cell tumors,
including choriocarcinomas may arise from germ cells
that failed to complete their migration to the gonads
[8]. However, germ cell choriocarcinomas arising from
the female genital tract in postmenopausal woman with
normal ovaries on CT scan and sonography are extre-
mely rare [3,9].
When choriocarcinoma occurs in postmenopausal
woman, it is difficult to rule out the possibility of tro-
phoblastic differentiation within an endometrial carci-
noma. Choriocarcinoma has been reported in
association with endometrial carcinoma as well as liver,
lung and urinary bladder carcinomas [10]. These types
of choriocarcinomas can be diagnosed based on histol-
ogy (that is, coexisting malignant cells other than chor-
iocarcinoma cells). Khuu et al.r e p o r t e dac a s eo f
uterine carcinosarcoma with choriocarcinomatous dedif-
ferentiation in a 71-year-old woman [10]. In that case,
histology results suggested choriocarcinoma intermixed
with adenocarcinoma and stromal sarcoma. While, in
our patient, there was no evidence of endometrial ade-
nocarcinoma. The non-lesional endometrium showed
decidualization. These findings would rule out dediffer-
entiation within an endometrial carcinoma. A report
from Chumworathayi et al. described cervical choriocar-
cinoma with metaplastic transformation from squamous
cells [11]. The authors discussed the possibility of in
situ squamous cell carcinoma, which may not be initially
diagnosed on small tissue biopsy. In our patient, an
endometrial biopsy showed malignant syncytiotropho-
blasts and cytotrophoblasts associated with inactive,
non-malignant endometrial glands and decidual reaction
in normal-appearing endometrium (Figure 1).
Immunohistochemistry analysis is useful in differential
diagnosis of choriocarcinoma. Strong diffuse b-hCG
immunoreactivity confirms the diagnosis of choriocarci-
noma. OCT-3/4, CD-30 and AFP are markers of various
germ cell tumors [12]. OCT-3/4 is a transcription factor,
expressed in undifferentiated pluripotent cells including
germ cells. CD-30 is a member of the tumor necrosis
factor superfamily of cytokine receptors. Positive stain-
ing for CD-30 has been used for diagnosis of embryonal
carcinoma. OCT-3/4 and CD-30 can be used in combi-
nation to establish the germ cell origin of any metastatic
tumor. Negative staining for both markers helps in rul-
ing out a germ cell origin of such tumors [12-14]. AE1/
AE3 is a combination of two pancytokeratin antibodies,
AE1 and AE3. AE1/AE3 staining is usually positive in
choriocarcinomas as cytokeratin is expressed on tropho-
blastic cells (trophoblastic cells are derived from epithe-
lial cells) [13,15]. Various serum tumor markers (b-hCG,
AFP and CA-125) are also useful in the differential diag-
nosis of choriocarcinoma. It is well known that elevated
AFP and CA-125 levels are seen in non-seminomatous
germ cell tumors and ovarian carcinomas, respectively
[16]. As discussed above, in our patient immunohisto-
chemistry analysis was positive for b-hCG (Figure 1)
and cytokeratins (AE-1/AE-3 antibodies), while staining
of OCT-3/4, CD-30 and AFP was negative. Therefore,
negative staining with OCT-3/4, CD-30 and AFP antibo-
dies as well as normal AFP and CA-125 levels suggested
a gestational origin of the tumor.
Fisher et al. demonstrated DNA polymorphism studies
are the most specific to confirm a gestational origin of
tumor [3]. These studies compare microsatellite poly-
morphism between the patient, tumor and partner’s
DNA (if available) by examination of restriction frag-
ment length polymorphisms (RFLPs) using locus specific
microsatellites. Genetic studies are useful when the
patient’s history and pathological review are insufficient
for diagnosis. However, they are time consuming and do
not always give conclusive results.
Based on American Joint Committee on Cancer
(AJCC) staging guidelines for gestational trophoblastic
tumors (GTT), our patient had stage IVB cancer (con-
sidering high b-hCG and clinical liver metastasis) [17].
Treatment guidelines for choriocarcinomas in postme-
nopausal woman are not well defined. However, pre-
vious studies have suggested that an effective first-line
therapy for high-risk gestational trophoblastic tumor is
the combination of etoposide, methotrexate, and dacti-
nomycin, followed by cyclophosphamide and vincris-
tine (the EMA/CO regimen) [18]. However, full
genetic analysis from tumor biopsies and patient DNA
is time consuming and does not always yield conclu-
sive results [3]. Therefore, based upon histology, serum
tumor markers and immunochemistry analysis, we
initiated treatment with EMA-CO. Our patient
responded well to this regimen as seen clinically (reso-
lution of vaginal bleeding), as well as radiologically (a
normal-appearing uterus and decrease in size of
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was confirmed by a decrease in b-hCG level. The che-
motherapy regimen was repeated every two weeks for
five cycles. At the end of five cycles, our patient’s b-
hCG level plateaued around 10 mIU/mL. We repeated
this regimen for two more cycles until remission (nor-
malization of b-hCG) was achieved.
The molecular mechanism behind the long latent
period between development of a choriocarcinoma and
last pregnancy has not been described. In our patient,
it is theoretically possible that she became pregnant
after her last known gestation (before 38 years) but
without clinical symptoms. However, our patient con-
siders this to be unlikely. Even if we consider the pos-
sibilities of asymptomatic gestation developing in
choriocarcinoma, our patient has an established meno-
pause of 23 years. To date, there are very few case
reports in the global literature of gestational diseases
in postmenopausal women. Reports of choriocarci-
noma are even more rare [1,3,4,9-11,19-21]. Tsuka-
moto et al. reported three postmenopausal patients
with choriocarcinoma, with the periods between the
last pregnancy and development of tumor being 11, 15
and 18 years [22]. O’Neill et al.a n dO k a m o t oet al.
reported choriocarcinoma 22 and 23 years after last
pregnancy, respectively [4,5].
Conclusions
To the best of our knowledge, this is the first case of
choriocarcinoma after a latent period of 38 years after
last pregnancy and 23 years after menopause
[3-5,9,19,20]. Germ cell choriocarcinoma confirmed
by DNA analysis is extremely rare and has previously
only been reported in women of child bearing age
[3,23]. In our patient’s case, we do not rule out the
possibility of a non-gestational choriocarcinoma, but
the response to chemotherapy with histology, immu-
nohistochemistry and serum tumor markers suggested
a gestational origin. The prognosis of germ cell chor-
iocarcinoma is extremely poor despite chemotherapy
and surgery. Therefore, we encourage not delaying
patient management while awaiting DNA analysis
results. Treatment with a combination chemotherapy
regimen such as EMA/CO should be initiated imme-
diately after establishing a diagnosis of choriocarci-
noma with the help of histology, tumor markers and
immunohistochemistry.
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